Capsida Presents New Data from GLP Toxicology Study in NHPs Demonstrating Potential Best-in-Class Profile of CAP-003 in Patients with Parkinson’s Disease Associated with GBA Mutations (PD-GBA)

GCase elevations meaningfully exceeding efficacy threshold, well-tolerated safety profile, and IV-administration support advancing CAP-003 into clinical development in 1H25. THOUSAND OAKS, Calif., April 3, 2025 /PRNewswire/ — Capsida Biotherapeutics (“Capsida”) today announced new data…